Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate High-risk, locally advanced disease (T2b-T4 disease), meeting 1 of the following criteria: Gleason score 8-10 Prostate-specific antigen > 20 ng/dL AND Gleason score 7 T2a disease allowed provided ≥ 5 biopsies contain Gleason score 4 +3 cancer (minimum of 10 biopsies total required) No evidence of metastatic disease within the past 60 days by physical examination, chest x-ray, bone scan, and CT scan of abdomen and pelvis PATIENT CHARACTERISTICS: ECOG performance status 0-2 Hemoglobin > 8 g/dL Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 times upper limit of normal (ULN) Creatinine ≤ 1.5 times ULN Blood pressure ≤ 150/100 mm Hg No cardiovascular disease, including any of the following: Unstable angina New York Heart Association class II-IV congestive heart failure History of myocardial infarction within the past 6 months History of stroke within the past 6 months PRIOR CONCURRENT THERAPY: At least 4 weeks since prior major surgery No prior hormonal therapy (except finasteride for obstructive voiding symptoms) for prostate cancer No prior or concurrent chemotherapy, biologic therapy, or radiotherapy for prostate cancer